disopyramide


Also found in: Dictionary, Wikipedia.
Related to disopyramide: lidocaine, amiodarone

disopyramide

 [di″-so-pēr´ah-mīd]
an agent used to control cardiac arrhythmias; it suppresses and prevents recurrence of both unifocal premature ventricular contractions and those of multifocal origin, paired premature ventricular contractions, and episodes of ventricular tachycardia that are not persistent.

disopyramide

Norpace® An antiarrhythmic

disopyramide

A drug used to prevent or control disturbances of heart rhythm. Brand names are Dirythmin SA and Rythmodan.
References in periodicals archive ?
All of the antiarrhythmic agents had strong and relatively comparable evidence of efficacy compared with control treatment, and the point estimates were all consistent with fairly large treatment effect sizes: quinidine (OR=4.1; 95% CI, 2.5-6.7)[18,41-43]; disopyramide (OR=3.4; 95% CI, 1.6-7.1)[44-45]; flecainide (OR=3.1; 95% CI, 1.5-6.2)[46-48]; propafenone (OR=3.7; 95% CI, 2.4-5.7)[27,49-51]; and sotalol (OR--7.1; 95% CI, 3.8-13.4).[37,49]
QT prolongation refers to the prolonged QT interval in electrocardiography (ECG) which can even lead to life-threatening events such as ventricular arrhythmias, torsades de pointes, etc., several drugs can cause QT prolongation which includes sotalol, quinidine, arsenic, disopyramide, procainamide, amiodarone, haloperidol, etc., Arsenic trioxide (ATO) is used as an effective treatment option in promyelocytic leukemia (PML).
If antiarrhythmic therapy Is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of LATUDA.
(a) Antiarrhythmic drugs: Class 1A (quinidine, procainamide, and disopyramide), Class 1C (encainide, flecainide), and Class 3 (sotalol, dofetilide)
This type of effect is similar to the antiarrhythmic effects of disopyramide and quinidine, and its activity has been shown in animal models and human atrial cells in vitro.
SOME DRUGS THAT CAN CAUSE OR EXACERBATE HEART FAILURE Condition Drugs Arrhythmia dronedarone, flecainide, disopyramide, sotalol Cancer anthracydines and many other agents Depression citalopram, lithium Diabetes thiazolidinediones, dipeptidyl peptidase-4 inhibitors Fungal infections amphotericin B Hypertension doxazosin, diltiazem, verapamil, moxonidine Malaria chloroquine, hydroxychloroquine Migraines ergotamine, methysergide Pain prescription and nonprescription NSAIDs Parkinson's pergolide, pramipexole, bromocriptine Platelet disorders anagrelide, cilostazol Pulmonary disease bosentan, epoprostenol, albuterol Rheumatologic TNF-a inhibitors diseases
Medications include beta blockers, calcium channel blockers, and, rarely, diltiazem, amiodarone, and disopyramide. The hypertrophic cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiarrhythmic agents, anticoagulants, beta adrenergic blocking agents, and calcium channel blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2015 to 2020).
Isotachophoretic determination of bisoprolol, clonidine, disopyramide and tolazoline in human fluids.
Beta blockers, Verapamil, Amiodarone, Disopyramide or Quinidine may be given.
Quinine is not recommended for use with other drugs known to cause QT prolongation, including Class IA antiarr- hythmic agents (e.g., quinidine, procainamide, disopyramide), and Class III antiarrhythmic agents (e.g., amiodarone, sotalol, dofetilide).
AFib is often initially treated with antiarrhythmic drugs, such as amiodarone (Cordarone, Pacerone), bepridil hydrochloride (Vascor), or disopyramide (Norpace).